Today, the board of directors of FIT Biotech Oy (the 'Company') decided on the conversion of shares representing different series of shares in the Company in accordance with the conversion commitments submitted by the shareholders to the Company.
The board decided on the conversion of 1,915 A shares and 27,900 D shares into K shares and 1,000 D shares into A shares in accordance with section 5 of the Company's articles of association (1:1). After the conversion, the Company will have 27,596,817 K shares, 5,229 A shares and 68,235 D shares. The total number of shares in the Company, 27,670,281, is not affected by the conversion.
The Company's K shares are traded under the trading symbol FITBIO on the multilateral First North market maintained by the Helsinki Stock Exchange.
The conversions of shares will be entered into the Trade Register on or about 20 July 2015, and the trading of the converted K shares on First North will begin on or about 22 July 2015.
Additional information:
CEO Kalevi Reijonen, FIT Biotech Oy
Email: kalevi.reijonen@fitbiotech.com
Phone: +358 40 843 5695
Board member Tina Nyfors, FIT Biotech Oy
Phone: +358 40 843 9502